Puma Biotechnology, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $56.5M | $44.8M | $75.5M | $54.5M | $52.4M | $46.0M | $59.1M | $80.5M |
| Cost of Revenue | $12.5M | $10.4M | $23.1M | $12.2M | $12.3M | $10.6M | $13.9M | $29.1M |
| Gross Profit | $44.0M | $34.4M | $52.3M | $42.3M | $40.1M | $35.5M | $45.2M | $51.4M |
| Gross Margin | 77.9% | 76.7% | 69.3% | 77.7% | 76.5% | 77.1% | 76.4% | 63.9% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $17.5M | $18.4M | $18.4M | $16.8M | $18.0M | $17.6M | $16.6M | $16.8M |
| Operating Income | $7.6M | $-3.8M | $17.1M | $9.6M | $6.6M | $4.0M | $13.4M | $22.1M |
| Operating Margin | 13.4% | -8.5% | 22.7% | 17.6% | 12.7% | 8.7% | 22.6% | 27.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $8.2M | $-3.4M | $17.1M | $9.2M | $6.2M | $3.3M | $12.2M | $20.6M |
| Income Tax Expense | — | — | — | — | — | — | $-7.1M | $291.0K |
| Net Income | $8.2M | $-3.8M | $13.4M | $8.8M | $5.9M | $3.0M | $19.3M | $20.3M |
| Net Margin | 14.5% | -8.4% | 17.8% | 16.2% | 11.2% | 6.5% | 32.7% | 25.2% |
| EPS (Basic) | $0.16 | $-0.07 | $0.26 | $0.18 | $0.12 | $0.06 | $0.40 | $0.41 |
| EPS (Diluted) | $0.16 | $-0.07 | $0.26 | $0.17 | $0.12 | $0.06 | $0.40 | $0.41 |
| Shares Outstanding (Basic) | 50.9M | 50.8M | 50.0M | 50.3M | 49.7M | 49.6M | 48.6M | 49.0M |
| Shares Outstanding (Diluted) | 52.6M | 50.8M | 50.7M | 50.9M | 50.1M | 49.9M | 49.1M | 49.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |